# US 5,708,011 A · Use of levobupivacaine in a patient having depressed myocardial contractility

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,708,011 A
- Document ID: US5708011A
- Status: Granted
- Kind: A
- Application number: 08/640,930
- Filed: 1996-04-12
- Granted: 1998-01-13
- Earliest claimed: 1993-10-13
- Assignees: Chiroscience Limited
- Inventors: Hazel Judith Bardsley; Robert William Gristwood
- Web page: https://patentgrep.com/patent/US5708011A

## CPC

- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 23/00: Anaesthetics
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This application relates to methods of using levobupivacaine substantially free of dexbupivacaine for anaesthetic treatment of pain in a patient having depressed myocardial contractility.

## Claims

### Claim 1

A method for anaesthetic treatment of pain in a human patient having or disposed to having depressed myocardial contractility, said method comprising the administration of an effective amount of levobupivacaine or a salt thereof, to said patient, wherein said levobupivacaine is substantially free of dexbupivacaine.

### Claim 2 (depends on 1)

The method, according to claim 1, wherein the patient is suffering from a condition selected from the group consisting of hypertension, renal disease, a post-myocardial infarct, ischaemia, diabetes, viral infection, and alcohol dependence.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the patient has undergone cardiac surgery, multiple organ failure or a valve replacement, or has been fitted with a pacemaker.

### Claim 4 (depends on 1)

The method, according to claim 1, wherein the patient is undergoing concomitant therapy with a cardio-depressant drug.

### Claim 5 (depends on 1)

The method, according to claim 1, wherein the patient is undergoing concomitant anti-hypertension therapy, by the administration of a Ca.sup.2+ channel blocker.

### Claim 6 (depends on 1)

The method, according to claim 1, wherein the patient is undergoing concomitant therapy with a cytotoxic drug.

### Claim 7 (depends on 1)

The method, according to claim 1, wherein the levobupivacaine is in at least 90% enantiomeric excess with respect to dexbupivacaine.

### Claim 8 (depends on 5)

The method, according to claim 5, wherein said Ca.sup.2+ channel blocker comprises verapamil.

### Claim 9 (depends on 1)

The method, according to claim 1, wherein the patient is suffering from, or disposed to, heart failure at level 2, 3, or 4 of the New York Heart Association Scale.